10.1007/s40089-015-0169-0

Albumin microparticles as the carriers for allopurinol and applicable for the treatment of ischemic stroke

HTML PDF
  • Hovsep Alexandr Aganyants1,
  • Gayane Nikohosyan2,
  • Kristine Edgar Danielyan*1,
  1. H. Buniatian Institute of Biochemistry, National Academy of Science, RA, Yerevan, 0014, AM
  2. H. Buniatian Institute of Biochemistry, National Academy of Science, RA, Yerevan, 0014, AM Yerevan State University, Yerevan, AM
Cover Image

Published in Issue 2015-11-09

How to Cite

Aganyants, H. A., Nikohosyan, G., & Danielyan, K. E. (2015). Albumin microparticles as the carriers for allopurinol and applicable for the treatment of ischemic stroke. International Nano Letters, 6(1 (March 2016). https://doi.org/10.1007/s40089-015-0169-0
Crossref
Scopus
Google Scholar
Europe PMC

HTML views: 21

PDF views: 113

Abstract

Abstract Albumin nanoparticles are already used for the treatment of the cancer. In our current work, it is presented the technique for the preparation of small-size 1- to 5-micron particles coated with the allopurinol. We propose that this combination of the compounds might be useful for the ischemic stroke treatment as the agent preventing formation of the brain edema, reactive oxygen species, and initiation of cells regeneration. Glutaraldehyde was used for the polymerization of albumin. Determination of the particle size was performed by the light as well as phase contrast microscopies and analyzed by Pixcavator 6.0 and Image Tool programs. Modification and establishment of iodine-based method served as the base for quantification of bound with the particles and free allopurinol. As a consequence of the experiments, the best formulation of glutaraldehyde ratio and albumin quantity as well as conditions for the formation of the smallest sized spheroid-shaped particles were found for the further in vivo application.

Keywords

  • Albumin,
  • Particles,
  • Allopurinol,
  • Cancer,
  • Stroke
HTML PDF

References

  1. Peters (1996) Academic Press Limited
  2. Sudlow and Birkett (1976) Further characterization of specific drug binding sites on human serum albumin (pp. 1052-1061)
  3. de Wolf and Brett (2000) Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands 52(2) (pp. 207-236)
  4. Curry (2009) Lessons from the crystallographic analysis of small molecule binding to human serum albumin (pp. 342-357) https://doi.org/10.2133/dmpk.24.342
  5. Curry and Brick (1999) Fatty acid binding to human serum albumin: new insights from crystallographic studies (pp. 131-140) https://doi.org/10.1016/S1388-1981(99)00148-1
  6. Bhattacharya and Grüne (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin (pp. 721-732) https://doi.org/10.1006/jmbi.2000.4158
  7. Sudlow and Birkett (1975) The characterization of two specific drug binding sites on human serum albumin (pp. 824-832)
  8. Zunszain and Ghuman (2008) Crystallographic analysis of human serum albumin complexed with 4Z, 15E-bilirubin-IXα 381(2) (pp. 394-406) https://doi.org/10.1016/j.jmb.2008.06.016
  9. Kragh-Hansen (1981) Molecular aspects of ligand binding to serum albumin (pp. 17-53)
  10. Evans (2002) Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure 16(Suppl. 5) (pp. 6-11) https://doi.org/10.1046/j.1365-2036.16.s5.2.x
  11. Elzoghby and Samy (2012) Protein-based nanocarriers as promising drug and gene delivery systems (pp. 38-49) https://doi.org/10.1016/j.jconrel.2012.04.036
  12. Nitta and Numata (2013) Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering 14(1) (pp. 1629-1654) https://doi.org/10.3390/ijms14011629
  13. Dawson and Quinn (2009) The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial 68(5) (pp. 662-668) https://doi.org/10.1111/j.1365-2125.2009.03497.x
  14. Taheraghdam and Sharifipour (2014) Allopurinol as a preventive contrivance after acute ischemic stroke in patients with a high level of serum uric acid: a randomized, controlled trial 23(2) (pp. 134-139)
  15. Kim and Jiang (2011) Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution 100(2) (pp. 482-491) https://doi.org/10.1002/jps.22298
  16. Sebak and Mirzaei (2010) Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis (pp. 525-532)
  17. Zhang and Hou (2010) Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles 33(8) (pp. 1193-1198) https://doi.org/10.1007/s12272-010-0809-x
  18. Li and Su (2008) Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting 349(1–2) (pp. 274-282) https://doi.org/10.1016/j.ijpharm.2007.08.001
  19. Zhao and Su (2014) Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation (pp. 2149-2156) https://doi.org/10.2147/IJN.S60764
  20. Suprun (1971) Improvement of existing and elaboration of new technic of iodometric quantitative determination of xanthine derivatives by formation of periodide 26(5) (pp. 65-69)
  21. Arzamaszev, A.P.: Pharmchemistry course, 2nd edn, p. 319. Medicine, Moscow (1995)
  22. Lee and Ye (2011) Formulation, pharmacokinetics and biodistribution of ofloxacin-loaded albumin microparticles and nanoparticles 28(5) (pp. 363-369) https://doi.org/10.3109/02652048.2011.569766
  23. Sitta and Guilherme (2013) Covalent albumin microparticles as an adjuvant for production of mucosal vaccines against hepatitis B 14(9) (pp. 3231-3237) https://doi.org/10.1021/bm400859z
  24. Sitta and Guilherme (2014) Drug release mechanisms of chemically cross-linked albumin microparticles: effect of the matrix erosion (pp. 404-413) https://doi.org/10.1016/j.colsurfb.2014.07.014
  25. Zhao and Zhao (2010) Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles (pp. 669-677)
  26. Danielyan (2013) Dependence of cells survival from xanthine oxidase and dihydopyrimidine dehydrogenase correlative activities in human brain derived cell culture 13(2) (pp. 108-113) https://doi.org/10.2174/1871524911313020003
  27. Danielyan and Chailyan (2013) Xanthine dehydrogenase inhibition stimulates growth and development of human brain derived cells 1(4) (pp. 95-98) https://doi.org/10.12691/ajmbr-1-4-2
  28. Gyongyan, S.A., Manucharyan, T.G., et al.: Xanthine oxidoreductase is a key enzyme of purine catabolism regulation. Electron. J. Nat. Sci.
  29. 5
  30. (2), 17 (2013)
  31. Belayev and Saul (2005) Albumin treatment reduces neurological deficit and protects blood–brain barrier integrity after acute intracortical hematoma in the rat 36(2) (pp. 326-331) https://doi.org/10.1161/01.STR.0000152949.31366.3d
  32. Hill and Martin (2011) The albumin in acute stroke part 1 trial: an exploratory efficacy analysis. ALIAS investigators; neurological emergencies treatment trials network 42(6) (pp. 1621-1625) https://doi.org/10.1161/STROKEAHA.110.610980